The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder.
Botulinum toxin type A
Clean intermittent catheterization
Demographics
Overactive bladder
Postvoid residual volume
Urinary incontinence
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
20
09
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Transient increases in postvoid residual urine volume (PVR) requiring clean intermittent catheterization (CIC) have occurred with onabotulinumtoxinA treatment for overactive bladder (OAB). To evaluate onabotulinumtoxinA safety and the effect of age, gender, and maximum PVR (PVR This was a pooled post hoc analysis of four placebo-controlled, multicenter randomized trials that included adults with idiopathic OAB after first onabotulinumtoxinA treatment (NCT00910845, NCT00910520, NCT01767519, NCT01945489). Patients had at least three urgency UI episodes over 3 d and at least eight micturitions per day, had inadequate management with at least one anticholinergic agent, and were willing to use CIC. We measured the following outcomes: PVR Of 1504 patients, 87.7% were women and 88.8% were White. The mean age was 60.5 yr across 10-yr age groups, baseline PVR was 13.8-35.0 ml, and estimated functional capacity was 293.5-475.7 ml. Mean baseline PVR was 21.3 ml overall versus 34.0 ml in the group that started CIC. The CIC incidence was 6.2% for women (range 1.1-8.4%) and 10.5% for men (range 0-14.6%). Higher CIC rates were observed for PVR CIC incidence was low overall, was less frequent for women, was rare with PVR After onabotulinumtoxinA treatment for OAB, patients sometimes insert a catheter to help in emptying their bladder after urinating. In this study, few patients needed a catheter, especially when less urine volume remained after urination.
Sections du résumé
Background
UNASSIGNED
Transient increases in postvoid residual urine volume (PVR) requiring clean intermittent catheterization (CIC) have occurred with onabotulinumtoxinA treatment for overactive bladder (OAB).
Objective
UNASSIGNED
To evaluate onabotulinumtoxinA safety and the effect of age, gender, and maximum PVR (PVR
Design setting and participants
UNASSIGNED
This was a pooled post hoc analysis of four placebo-controlled, multicenter randomized trials that included adults with idiopathic OAB after first onabotulinumtoxinA treatment (NCT00910845, NCT00910520, NCT01767519, NCT01945489). Patients had at least three urgency UI episodes over 3 d and at least eight micturitions per day, had inadequate management with at least one anticholinergic agent, and were willing to use CIC.
Outcome measurements and statistical analysis
UNASSIGNED
We measured the following outcomes: PVR
Results and limitations
UNASSIGNED
Of 1504 patients, 87.7% were women and 88.8% were White. The mean age was 60.5 yr across 10-yr age groups, baseline PVR was 13.8-35.0 ml, and estimated functional capacity was 293.5-475.7 ml. Mean baseline PVR was 21.3 ml overall versus 34.0 ml in the group that started CIC. The CIC incidence was 6.2% for women (range 1.1-8.4%) and 10.5% for men (range 0-14.6%). Higher CIC rates were observed for PVR
Conclusions
UNASSIGNED
CIC incidence was low overall, was less frequent for women, was rare with PVR
Patient summary
UNASSIGNED
After onabotulinumtoxinA treatment for OAB, patients sometimes insert a catheter to help in emptying their bladder after urinating. In this study, few patients needed a catheter, especially when less urine volume remained after urination.
Identifiants
pubmed: 38020522
doi: 10.1016/j.euros.2023.09.013
pii: S2666-1683(23)01288-0
pmc: PMC10658411
doi:
Types de publication
Journal Article
Langues
eng
Pagination
98-105Informations de copyright
© 2023 The Author(s).
Références
BJU Int. 2008 Jun;101(11):1388-95
pubmed: 18454794
Int Urogynecol J. 2018 Jul;29(7):1005-1009
pubmed: 28808734
J Urol. 2013 Jun;189(6):2186-93
pubmed: 23246476
Eur Urol. 2013 Aug;64(2):249-56
pubmed: 23608668
Toxins (Basel). 2016 Mar 25;8(4):91
pubmed: 27023603
Female Pelvic Med Reconstr Surg. 2021 Jul 1;27(7):450-456
pubmed: 32665528
Toxins (Basel). 2020 Mar 09;12(3):
pubmed: 32182780
Curr Med Res Opin. 2018 Oct;34(10):1771-1776
pubmed: 29458265
J Urol. 2017 Jul;198(1):167-175
pubmed: 28161352
Urology. 2012 Jul;80(1):90-6
pubmed: 22748867
World J Urol. 2003 May;20(6):327-36
pubmed: 12811491
Ther Adv Urol. 2021 Aug 31;13:17562872211039034
pubmed: 34484427
J Urol. 2015 May;193(5):1572-80
pubmed: 25623739
Am J Physiol Regul Integr Comp Physiol. 2014 Oct 1;307(7):R893-900
pubmed: 25100077
Neurourol Urodyn. 2015 Sep;34(7):675-8
pubmed: 24975819
Indian J Pharmacol. 2010 Oct;42(5):261-6
pubmed: 21206614
Int Urogynecol J. 2017 Sep;28(9):1351-1356
pubmed: 28116467
Taiwan J Obstet Gynecol. 2021 May;60(3):513-516
pubmed: 33966738
J Am Geriatr Soc. 2015 Jul;63(7):1432-4
pubmed: 26189846